Hydrophobic lenses produce less PCO than hydrophilic lenses

Article

Patients implanted with a hydrophilic intraocular lens (IOL) develop more posterior capsule opacification (PCO) and have worse visual acuity (VA), contrast sensitivity and glare after two years, compared with patients implanted with a hydrophobic IOL.

Patients implanted with a hydrophilic intraocular lens (IOL) develop more posterior capsule opacification (PCO) and have worse visual acuity (VA), contrast sensitivity and glare after two years, compared with patients implanted with a hydrophobic IOL, according to Charlotta Zetterström and colleagues of St Erik's Eye Hospital, Stockholm, Sweden.

Cataract surgery was performed in one eye of 120 subjects, who were randomized to receive either the hydrophilic BL27 (Bausch & Lomb) or the hydrophobic AcrySof SA60AT IOL (Alcon). Both IOLs are acrylic, single-piece lenses with a sharp edge.

After two years, the hydrophilic IOL group demonstrated significantly more PCO than the hydrophobic group, with both a greater severity (p<0.001) and area (p<0.001). Women in the hydrophobic group had significantly more PCO than men (p<0.05) for severity and area. Best corrected visual acuity (BCVA) was also not as good in the hydrophilic group (p<0.01) and this group also showed poorer contrast sensitivity (p<0.01) and more glare (p<0.001) compared with the hydrophobic group.

The researchers concluded that hydrophobic lenses result in less PCO than hydrophilic lenses after two years.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.